Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8:16:1624322.
doi: 10.3389/fphar.2025.1624322. eCollection 2025.

Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study

Jing Xue  1   2   3 , Zhihao Lian  4 , Xiaoyan Li #  1   2   3
Affiliations

Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study

Jing Xue et al. Front Pharmacol. .

Abstract

Introduction: Oxaliplatin (OXA) serves as a first-line treatment for digestive system tumors such as colorectal cancer (CRC) and gastric cancer. OXA-induced hypersensitivity reactions (HSRs) may pose life-threatening risks to patients. This study aimed to explore the risk factors and protective factors of OXA-induced HSRs in Chinese CRC patients.

Methods: A retrospective analysis was conducted on 233 CRC patients who received OXA treatment between June 2022 and December 2022. Demographic data and medical histories were extracted from the hospital's medical record system.

Results: Among the 233 patients, 51 patients (21.9%) developed OXA-induced HSRs, with the median treatment cycle at onset being the 4th cycle. Univariate and multivariate analyses revealed that an OXA treatment interruption lasting ≥30 days (P < 0.05, odds ratio [OR] = 10.76, 95% confidence interval [CI] = 4.57-25.3), a history of platinum-based drug allergy (P < 0.05, OR = 19.03, 95% CI = 1.66-217.99), and abnormal absolute neutrophil count (P < 0.05, OR = 8.96, 95% CI = 3.11-25.86) were independent risk factors. Pretreatment with dual-drug or triple-drug prophylactic regimens before OXA administration was identified as an independent protective factor (P < 0.05, OR = 0.37, 95% CI = 0.17-0.82). The area under the receiver operating characteristic (ROC) curve was 0.82 (P < 0.001, 95% CI = 0.75-0.89). Although previous platinum-based drug dosage and abnormal absolute lymphocyte count showed significant differences in univariate analysis, they did not emerge as independent influencing factors in multivariate logistic regression.

Conclusion: Prolonged OXA treatment interruption, a history of platinum-based drug allergy, and abnormal neutrophil count are independent risk factors for OXA-induced HSRs, while dual/triple-drug pretreatment acts as an independent protective factor. Clinicians should evaluate these risks before medication and consider intensified pretreatment regimens to reduce HSR incidence.

Keywords: colorectal cancer; hypersensitivity reaction; oxaliplatin; protective factors; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The patient exclusion process in the retrospective study.
FIGURE 2
FIGURE 2
The ROC curve for the final predictive model demonstrates an AUC of 0.82.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Aroldi F., Prochilo T., Bertocchi P., Zaniboni A. (2015). Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J. Chemother. 27 (2), 63–66. 10.1179/1973947814y.0000000204 - DOI - PubMed
    1. Bavbek S., Pagani M., Alvarez-Cuesta E., Castells M., Dursun A. B., Hamadi S., et al. (2022). Hypersensitivity reactions to biologicals: an EAACI position paper. Allergy 77 (1), 39–54. 10.1111/all.14984 - DOI - PubMed
    1. Benson A. B., Venook A. P., Adam M., Chang G., Chen Y. J., Ciombor K. K., et al. (2024). Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 22 (2 d), e240029. 10.6004/jnccn.2024.0029 - DOI - PubMed
    1. Cao K., Hollenbach J., Shi X., Shi W., Chopek M., Fernández-Viña M. A. (2001). Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62 (9), 1009–1030. 10.1016/s0198-8859(01)00298-1 - DOI - PubMed
    1. Castells M., Sancho-Serra Mdel C., Simarro M. (2012). Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol. Immunother. 61 (9), 1575–1584. 10.1007/s00262-012-1273-x - DOI - PMC - PubMed

LinkOut - more resources